{'fraction_non_alphanumeric': 0.02336028751123091, 'fraction_numerical': 0.008086253369272238, 'mean_word_length': 5.054347826086956, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Validity of pretransfusion bedside agglutination tests for pretransfusional control].

The incidence rate of ABO hazards of transfusion remains high in France. In this country, bedside pretransfusion controls include an agglutination test for red cells only, although its validity has scarcely been assessed in the practice. 847 nurses from 9 public hospitals and private clinics in a French region participated in a study aimed at measuring the sensitivity and specificity of pretransfusion bedside agglutination tests within hospital wards. Sensitivity was found to be 93.9% +/- 3%. Nondetection of mismatching was increased by two risk factors only: having worked more than 4 years in the same ward, and not having been trained to use this test. The sensitivity of this test might still be improved. This test is found sensitive enough to be kept. Nevertheless, if used alone, it is not a safe protection against recipient's mismatch. Authors recommend both to improve agglutination test sensitivity and to link it strongly to the bedside checking of both transfusion information and the recipient's identity.